Energy-based device commercialization achieved, injectable filler business steadily scaling up, combined treatment solutions create differentiated core advantages, continuously driving high-quality growth in the Asia-Pacific region
Hong KongJune 22, 2026 /PRNewswire/ — Sisram Medical Ltd (English: “Sisram“; referred to as the “Company” or “Sisram Medical“, stock code: 1696.HK), a global beauty and wellness group dedicated to building a customer-oriented beauty and wellness ecosystem centered on energy-based devices and injectable fillers, today announced that its Soprano series of energy-based devices have entered the Thailand market. Leveraging its localized direct sales structure and mature channel network, the Company has successfully completed the launch of both its energy-based device and injectable filler business lines in Thailand, further solidifying Thailand’s position as the Company’s core strategic hub in the Asia-Pacific region and continuously unlocking growth potential in the Southeast Asian market.
Relying on the direct sales operating system established in Thailand in 2025 and a deep-rooted local network of high-quality medical aesthetics institutions, Sisram Medical has smoothly facilitated the localized launch and commercial rollout of the Soprano series of energy-based devices. Since the product launch, end-user sales have steadily climbed, with positive feedback from partner institutions, marking the formation of a new dual-business parallel development landscape for the Company in Thailand. Looking ahead, the Company will advance the local registration and deployment of multiple new energy-based devices, with new product launches expected in the second half of 2026, continuously enriching the localized medical aesthetics device portfolio and refining regional product offerings.
Additionally, the sustained strong sales of core injectable filler products have solidified the foundation for the Company’s growth in the Thai market. Continuing the rapid growth momentum of 2025, Sisram Medical’s star product, Profhilo, has further penetrated Thailand’s high-end medical aesthetics market in 2026, gaining widespread recognition and favor from leading local high-quality medical aesthetics institutions and experienced physicians, with end-user sales maintaining steady growth. The continued deepening of this product not only reinforces the Company’s brand influence, market reputation, and institutional engagement in the injectable filler segment in Thailand but also lays a solid market foundation for the Company to deepen cooperation in the local medical aesthetics industry chain and expand medical aesthetics collaboration resources.
Leveraging the advantages of dual-business deployment, Sisram Medical is deeply exploring the synergistic value of its businesses, innovatively creating a differentiated combined treatment system that precisely meets the diverse and refined consumer demands of the Thai medical aesthetics market. The Company integrates the strengths of its core products, combining the firming, anti-aging, and skin texture improvement benefits of the Profhilo injectable filler with the proprietary technological advantages of the Soprano series of energy-based devices. Focusing on mainstream Thai medical aesthetics scenarios such as facial firming, lifting, and anti-aging, the Company has launched customized combination treatment plans.
This innovative business model not only significantly enhances the treatment experience and comprehensive therapeutic outcomes for aesthetic consumers, maximizing the commercial value of the full product portfolio, but also effectively boosts the core competitiveness and customer loyalty of partner institutions. This helps the Company achieve a comprehensive upgrade in product sales, partner channels, revenue scale, and profitability, building localized competitive advantages.
Mr. Eyal Ben David, Chief Executive Officer of Sisram Medical, stated: “Thailand is a core market for medical aesthetics consumption in Southeast Asia, boasting a mature healthcare service system, active local consumer demand, and a continuously rising trend in cross-border medical aesthetics tourism, offering vast market space for beauty and wellness solutions. Over the past year, we have deepened our localized operations in Thailand, achieving steady growth in revenue and profitability, delivering impressive market results.”
He further noted, “The breakthrough development in the Thai market is a powerful testament to the effectiveness of the Company’s global product layout, localized direct sales operating model, and dual-business synergy strategy. In the future, the Company will continue to focus on Thailand’s role as a strategic hub in the Asia-Pacific region, steadily expanding its local customer coverage, enhancing the medical education, technical empowerment, and after-sales support systems, and continuously deepening the synergistic development of the injectable filler and energy-based device businesses. By iterating high-end medical aesthetics solutions, we will comprehensively serve local aesthetic consumers and cross-border medical aesthetics clientele, continuously injecting new momentum into Sisram Medical’s long-term, high-quality, and sustainable growth in the Asia-Pacific region.”
About Sisram Medical
Sisram Medical Ltd (stock code: 1696.HK) is a global beauty and wellness group with over 25 years of professional experience in the energy-based device (EBD) field. Rooted in technological innovation and clinical excellence, the Company has built an ecosystem encompassing energy-based devices, injectable fillers, diagnostics, and synergistic solutions. With operations spanning more than 110 countries and regions worldwide, the Company sets a new benchmark in safe, effective, and personalized medical aesthetics care for millions of consumers globally through its award-winning, outstanding products. Sisram Medical is a majority-owned subsidiary of Fosun Pharma, a leading healthcare industry group in China, and has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.
For more information, please visit: www.sisram-medical.com.